SCHEMBL23705368

SCHEMBL23705368

C=C1COCc2ccc(Br)cc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP1 P53582 1/20 0.44
CHEK2 O96017 1/20 0.38
ROS1 P08922 1/20 0.38
MARK3 P27448 1/20 0.38
LTK P29376 1/20 0.38
FLT4 P35916 1/20 0.38
KDR P35968 1/20 0.38
MINK1 Q8N4C8 1/20 0.38
AURKB Q96GD4 1/20 0.38
PBK Q96KB5 1/20 0.38
STK17A Q9UEE5 1/20 0.38
MAP4K5 Q9Y4K4 1/20 0.38
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
PARP1 P09874 1/20 0.36
PARP10 Q53GL7 1/20 0.36
S100A4 P26447 1/20 0.33
MAOA P21397 3/20 0.33
MAOB P27338 3/20 0.33
TDP2 O95551 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30016060 0.85 METAP1 (0.49) METAP1CHEK2ROS1MARK3LTK
SCHEMBL17802101 0.85 METAP1 (0.49) METAP1CHEK2ROS1MARK3LTK
SCHEMBL23704955 0.84 METAP1 (0.41) METAP1CHEK2ROS1MARK3LTK
SCHEMBL3174866 0.77 PARP10 (0.43) METAP1CHEK2ROS1MARK3LTK
SCHEMBL29417669 0.74 PNMT (0.42) METAP1CHEK2ROS1MARK3LTK
SCHEMBL1362239 0.74 PNMT (0.42) METAP1CHEK2ROS1MARK3LTK
SCHEMBL6209711 0.74 METAP1 (0.46) METAP1CHEK2ROS1MARK3LTK
SCHEMBL30643139 0.74 METAP1 (0.46) METAP1CHEK2ROS1MARK3LTK
SCHEMBL29914776 0.74 TDP1 (0.52) METAP1CHEK2ROS1MARK3LTK
SCHEMBL3362722 0.74 TDP1 (0.52) METAP1CHEK2ROS1MARK3LTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
CN-115484948-A Compound and use thereof 福宏治疗公司 2022-12-16 CN disclosed
EP-4096657-A1 COMPOUNDS AND USES THEREOF Foghorn Therapeutics Inc. (US) 2022-12-07 EP disclosed
WO-2021155316-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 WO disclosed
WO-2021155316-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2021-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230149414-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB METAP1 4193/4885CHEK2 1608/4885ROS1 1853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.